CHK1 as a therapeutic target to bypass chemoresistance in AML.
David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE, Delabesse E, Cazaux C, Didier C, Récher C, Manenti S, Hoffmann JS.
David L, et al. Among authors: hoffmann js.
Sci Signal. 2016 Sep 13;9(445):ra90. doi: 10.1126/scisignal.aac9704.
Sci Signal. 2016.
PMID: 27625304
Clinical Trial.